Improved outlook, semaglutide rush may keep Glenmark stock in good health

Glenmark’s margin may get a further lift as the share of specialty products increases, global brands scale, and the US portfolio shifts towards complex generics

This is a summary fetched via RSS. For the full story, use the link above.